Investor Webinar

Summary by AI ^BETAClose X

TheraCryf plc will host an investor webinar on April 24, 2026, at 10:00 am BST, featuring the CEO and COO to discuss progress in their lead orexin-1 receptor antagonist program for addiction, which is moving towards clinical readiness and first-in-human studies. The company is also advancing its dopamine transporter modulator program for fatigue and has a legacy oncology program. Investors can submit questions in advance via the Investor Meet Company platform.

Disclaimer*

Theracryf PLC

21 April 2026

A black background with blue letters Description automatically generated

21 April 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Investor Webinar

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer, will host an investor webinar on Friday, 24 April 2026 at 10.00 am (BST).

The webinar will focus on the Company's recent announcements, including progress in its lead orexin-1 (Ox-1) receptor antagonist programme for addiction as it moves towards clinical readiness, alongside broader strategic developments as TheraCryf advances Ox-1 towards first-in-human studies.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Thursday, 23 April 2026, 9.00 am (BST), or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet TheraCryf via: https://www.investormeetcompany.com/theracryf-plc/register-investor

Investors who already follow TheraCryf on the Investor Meet Company platform will automatically be invited.

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

+44 (0)1625 315 090

enquiries@theracryf.com

Singer Capital Markets (NOMAD & Joint Broker)
Phil Davies / Patrick Weaver

+44 (0)20 7496 3000

Turner Pope Investments (Joint Broker)

Guy McDougall / Andy Thacker

+44 (0)20 3657 0050

Northstar Communications (Investor Relations)

Sarah Hollins

+44 (0)113 730 3896

sarah@northstarcommunications.co.uk

About TheraCryf

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need within central nervous system (CNS) disorders.

The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.

TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.

For further information, visit: https://theracryf.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END